eXoZymes Q3 10-Q: $7.49M Nine-Month Loss, Going Concern Reiterated, $3.26M Cash
EXOZ sits 18% above its 52-week low of $3.24 on elevated volume (2.1× avg).
Summary
eXoZymes reported a $7.49M nine-month net loss with $3.26M of cash and repeated its going-concern warning, keeping a fresh equity raise in view. A $946K warrant fair-value gain is non-cash and does not reflect new dilution.
Key Events · Earnings and Guidance · EXOZ
-
Nine-Month Net Loss Widens to $7.49M
Net loss was $7,487,389 for the nine months ended September 30, 2026 versus $6,503,698 a year earlier, driven by R&D costs up 60.9% to $4,176,128.
-
Going Concern Reiterated on Thin Cash
Cash stood at $3,258,901 with working capital of $2,210,334; management concluded existing working capital is not sufficient to fund operations for twelve months.
-
Warrant Gain Is Non-Cash Remeasurement
The $946,386 gain reflects the investor warrant liability falling from $2,075,471 at issuance to $1,129,085 at September 30 — a mark-to-market adjustment, not new dilution or cash.
-
Material Weakness Still Unremediated
Disclosure controls were again deemed not effective as of September 30, 2026 due to the previously disclosed material weakness in internal control over financial reporting.
Analysis · EXOZ · Life Sciences
The company remains pre-revenue and is burning cash: operations consumed $5,386,342 in the first nine months of 2026 against a $3,258,901 cash balance at September 30. Management states plainly that existing working capital will not fund twelve months of operations, so another raise is required — and the company already has an S-1 on file for an underwritten offering of up to $37.3M registered November 6, which is the most likely source. The $946,386 gain on the warrant liability is a non-cash mark-to-market adjustment on the June 2026 investor warrants, not new dilution or cash; the liability fell from $2,075,471 at issuance to $1,129,085 at quarter end. The previously disclosed material weakness in internal controls remains unremediated, and disclosure controls were again deemed not effective.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EXOZ was trading at $3.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.5M. The 52-week trading range was $3.24 to $18.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.